Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Perceptive Advisors and Foamix Pharmaceuticals Ltd.

Joe Edelman’s Perceptive Advisors tripled its Foamix Pharmaceuticals Ltd. (NASDAQ:FOMX) position following company’s offering. Edelman paid $6 per share for the 2.2 million share addition to his portfolio. Foamix is expected to raise about $80 million from last week’s public offering.

Joseph Edelman
Joseph Edelman
Perceptive Advisors

The details of his filing can be seen below.

Ownership Summary Table

Name Sole Voting Power Shared Voting Power Sole Dispositive Power Shared Dispositive Power Aggregate Amount Owned Power Percent of Class
Perceptive Advisors 0 3,307,424 0 3,307,424 3,307,424 6.3%
Joseph Edelman 0 3,307,424 0 3,307,424 3,307,424 6.3%
Perceptive Life Sciences Master Fund, Ltd 0 3,307,424 0 3,307,424 3,307,424 6.3%

Page 1 of 8 – SEC Filing





Under the Securities Exchange Act of 1934

(Amendment No.     )*



Pharmaceuticals Ltd.

(Name of Issuer)

Ordinary Shares, par value NIS 0.16 per share

(Title of Class of Securities)


(CUSIP Number)

September 14, 2018

(Date of Event Which Requires Filing of this Statement)



Check the appropriate box to
designate the rule pursuant to which this Schedule is filed:

☐ Rule 13d-1(b)

☒ Rule 13d-1(c)

Rule 13d-1(d)


The remainder of this cover page shall be filled out for a reporting persons initial filing on this form
with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be filed for the purpose of Section 18 of the Securities
Exchange Act of 1934 (Act) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).


Follow Foamix Pharmaceuticals Ltd. (NASDAQ:FOMX)
Trade (NASDAQ:FOMX) Now!